Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD
Oncotarget
.
2018 Nov 6;9(87):35721-35722.
doi: 10.18632/oncotarget.26291.
Authors
Kidist Ashami
1
,
John F DiPersio
1
,
Jaebok Choi
1
Affiliation
1
Jaebok Choi: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
PMID:
30515263
PMCID:
PMC6254668
DOI:
10.18632/oncotarget.26291
No abstract available
Keywords:
GvHD; IFNGR; IL6R; JAK1/JAK2; baricitinib.
Publication types
Editorial
Grants and funding
P50 CA171963/CA/NCI NIH HHS/United States
R35 CA210084/CA/NCI NIH HHS/United States